Teneligliptin Versus Linagliptin in Diabetes Mellitus Type Two Patients

• Status: Completed
• Trial end date: 2018-09-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess the efficacy and safety of Teneligliptin and Linagliptin in the type 2 Diabetes Mellitus patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Handok Inc.; Handok Pharmaceuticals Co., Ltd.
• Treatments: Linagliptin

Criteria

Inclusion Criteria:

• Patients who are 19 years or older on screening

• Patients with type 2 diabetes mellitus

• Patients with 7.0% ≤ HbA1c ≤ 11.0% at the screening visit

• Patients with Fasting Plasma Glucose <15mmol/L(270mg/dL) on screening

Exclusion Criteria:

-